OliX and Lilly Enter Global Licensing Agreement for MASH and …
2 days ago · OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s OLX75016. ... 226950), a leading developer of RNAi therapeutics, today ...
Lilly inks AdvanCell, OliX deals to expand in radiopharma, MASH
1 day ago · Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...
OliX and Lilly Enter Global Licensing Agreement for MASH and …
1 day ago · SEONGNAM, South Korea, February 10, 2025--OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s OLX75016.
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH
15 hours ago · Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...
Eli Lilly enters global license agreement with OliX for OLX75016
2 days ago · OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly . This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate primarily ...
OliX strikes $630 million deal with Lilly for obesity and liver …
1 day ago · OliX Pharmaceuticals, a Korean biotech company specializing in RNA interference (RNAi) therapies, has signed an exclusive global licensing deal with Eli Lilly worth up to $630 million. The agreement, announced last Friday, grants Lilly the rights to develop and commercialize OLX75016, an experimental RNAi-based treatment targeting metabolic ...
OliX and Lilly Enter Global Licensing Agreement for MASH and …
1 day ago · OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and Company (“Lilly”). This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis (MASH ...
OliX Pharmaceuticals signs 910 billion won deal with Eli Lilly, hits ...
2 days ago · OliX Pharmaceuticals, a gene therapy developer, recorded a daily limit up on the 10th after news that it signed a global license agreement worth 910 billion won with Eli Lilly. /Courtesy of OliX ...
Olix, Eli Lilly to develop liver disease drug under $630 million deal …
Olix will use the upfront payment to complete a phase 1 clinical trial for its candidate OLX702A in Australia while Eli Lilly will work on further research, development and commercialization.
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty …
1 day ago · Concurrently, Korea-based OliX Pharmaceuticals Inc. announced a global licensing agreement with Eli Lilly for the development and commercialization of OliX's OLX75016, a Phase 1 candidate ...
- Some results have been removed